AAI-101

Cas：1001404-83-6

Product Information：

AAI-101, also known as Enmetazobactam, is a beta lactamase inhibitor potentially for the treatment of multi-drug resistant gram-negative bacterial infections.

Chemical Formula: C11H14N4O5S

Exact Mass: 314.0685

Molecular Weight: 314.32

Elemental Analysis: C, 42.03; H, 4.49; N, 17.83; O, 25.45; S, 10.20

Synonym: 

AAI-101

AAI-101

AAI-101

Enmetazobactam

Chemical Name: (2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide

InChi Key: 

HFZITXBUTWITPT-YWVKMMECSA-N

InChi Code: InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1

Smiles Code:

C[N+]1=NN(C[C@@](S([C@]2([H])C3)(=O)=O)(C)[C@H](C([O-])=O)N2C3=O)C=C1

Technical Data：

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

In Vitro：

AAI101 shows potent activity against specific resistance phenotypes with MIC50 and MIC90 of 0.125 mg/L and 64 mg/L. Cefepime-AAI101 MICs decreases with increasing concentrations of AAI101 (over the range from 1 to 16 mg/L) for most strains, demonstrating a concentration dependence of AAI101 on restoration of the antibacterial activity of the cephalosporin.

In Vivo：

In neutropenic animals, cefepime-AAI101 treatment results in reductions in bacterial density of ≥0.5 log10 CFU for 12 of the 20 strains tested and reductions of ≥1 log10 CFU for 6 of these. Increases in bacterial density are for only four strains, three of which have cefepime-AAI101 MICs of ≥64 mg/L, irrespective of the AAI101 concentration.

References：

1. Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015 May;59(5):2688-94. doi: 10.1128/AAC.00033-15. PubMed PMID: 25712356; PubMed Central PMCID: PMC4394792.

2. Crandon JL, Nicolau DP. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens. 2015 Aug 18;4(3):620-5. doi: 10.3390/pathogens4030620. PubMed PMID: 26295262; PubMed Central PMCID: PMC4584277.

3. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Review. PubMed PMID: 26498989.

Products are for research use only. Not for human use.